trending Market Intelligence /marketintelligence/en/news-insights/trending/RBdyP2t95rGEQ2GCOu5iBw2 content esgSubNav
In This List

European Commission approves Roche's Alecensa for lung cancer subtype

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


European Commission approves Roche's Alecensa for lung cancer subtype

The European Commission granted marketing authorization for Chugai Pharmaceutical Co. Ltd.'s Alecensa as a first-line treatment of a certain lung cancer subtype.

Alecensa, or alectinib, is now approved as a monotherapy to treat patients with anaplastic lymphoma kinase-positive, or ALK-positive, metastatic non-small cell lung cancer, or NSCLC.

The approval is based on a phase 3 study which showed that the medicine significantly reduced the risk of disease worsening or death by 47% compared to Pfizer Inc.'s Xalkori, or crizotinib.

The medicine was also switched to full approval from conditional approval as a second-line treatment for patients with ALK-positive, metastatic NSCLC who have progressed on or are intolerant to Xalkori.

Roche Holding AG secured U.S. Food and Drug Administration approval for the first-line indication of Alecensa in November.

Tokyo-listed Chugai is a Roche subsidiary.